Overview
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Interactive group discussion on MDS
Click the "Register" button to register for this activity.
Register
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease and find out about emerging therapies that could soon revolutionize management of high-risk MDS. Be ready to incorporate these emerging therapies into your treatment plans to best meet the needs of your patients.
Professions: Physicians, Physician Assistants, Nurses
Specialties: Hematology, Medical Oncology, Pathology
Specialties: Hematology, Medical Oncology, Pathology
Myelodysplastic syndromes (MDS; also known as myelodysplastic neoplasms), a heterogenous group of disorders of the hematopoietic stem cells in the bone marrow, are associated with suboptimal numbers of one or more types of blood cells. Though relatively rare, the incidence of MDS has been steadily increasing as the average age of Americans has increased. The International Prognostic Scoring System-Revised (IPSS-R) has long been the gold-standard for patient risk stratification in MDS; however, a newer system, the IPSS-Molecular (IPSS-M) has been developed and validated to include newly elucidated gene mutations. Because the IPSS-M was introduced in 2022, clinicians on the multidisciplinary MDS team (eg, hematologists/oncologists, pathologists, advanced practice providers, and nurses) may not yet be familiar with its use for differentiating lower-risk from higher-risk patients. In addition, though a novel combination therapy, decitabine and cedazuridine, was approved in 2020 for MDS, there are few treatment options. Additional research and new therapies are still needed to improve outcomes for patients with high-risk MDS as median survival remains less than 2 years. Therefore, it is critical for multidisciplinary clinicians to familiarize themselves with newer pharmacologic targets for MDS, such as cluster of differentiation 47 (CD47). CD47 is a promising target as its overexpression has been associated with immune surveillance evasion. Clinicians also need to stay current with the latest data and clinical trials for a range of novel therapies in late-stage development for high-risk MDS. Considering the recent changes to MDS risk assessment, coupled with a multitude of promising emerging therapeutic options, it is critical that the multidisciplinary team understand these developments to ensure their implementation in practice to improve the management of patients with high-risk MDS.
Upon completion of this activity, participants will be able to:
• Apply updated classification guidelines in the evaluation of patients with MDS.
• Outline the role of immune surveillance and CD47 in the development of MDS.
• Discuss unmet patient needs in the treatment of HR-MDS.
• Describe the MOA of emerging therapies.
• Apply updated classification guidelines in the evaluation of patients with MDS.
• Outline the role of immune surveillance and CD47 in the development of MDS.
• Discuss unmet patient needs in the treatment of HR-MDS.
• Describe the MOA of emerging therapies.
The organizing committee wishes to express appreciation to the following company for their commitment to continuing medical education by providing an educational grant in support of this educational activity:
Gilead Sciences, Inc.
Daniel Pollyea, MD, MS
Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, CO
Guidelines require that learners in CME activities be made aware of all relevant financial relationships affecting the presentation of the faculty member. ACHL and the University of Texas MD Anderson Cancer Center ensure that all faculty and staff involved in the planning, development, and implementation of their activities disclose financial relationships held within 24 months and that relevant financial relationships are mitigated before a CME activity occurs. Complete information will be provided to learners prior to the start of the educational activity.
The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty & Planner Disclosure:
| Name of Individual | Individual's Role in Activity | Name of Ineligible Company(s)/ Nature of Relationship(s) |
| Katlyn Cooper | Planning Committee Member | Nothing to disclose |
| Courtney DiNardo, MD | Co-Director, Faculty | Honoraria-AbbVie, Daiichi Sankyo, Gilead Sciences, Inc. (Relationship has ended), Genentech, Astellas (Relationship has ended), Bristol Myers Squibb, GlaxoSmithKline, Jazz Pharmaceuticals, Novartis (Relationship has ended), Servier Pharmaceuticals, Immunogen (Relationship has ended) |
| Michelle Forcier, MS | Planning Committee Member | Nothing to disclose |
| Danya T. Garner, PhD, RN, NPD-BC, OCN, CCRN-K | Planning Committee Member, Nurse Planner | Nothing to disclose |
| Lisa Keckich, MS | Planning Committee Member | Nothing to disclose |
| Ritesh Kothari, MS | Planning Committee Member | Nothing to disclose |
| Natasha Mitchner, PhD | Planning Committee Member | Nothing to disclose |
| Anne Perch, MBA | Planning Committee Member | Nothing to disclose |
| Daniel Pollyea, MD | Co-Director, Faculty | Grant or research support-AbbVie, Bristol Myers Squibb, Teva Pharmaceuticals, Karyopharm Therapeutics; Honoraria-AbbVie (Relationship has ended), Novartis (Relationship has ended), Takeda (Relationship has ended), Kiadis (Relationship has ended), Foghorn (Relationship has ended), Aprea (Relationship has ended), Genentech, Syros (Relationship has ended), Gilead Sciences, Inc. (Relationship has ended), Astellas (Relationship has ended), Karyopharm Therapeutics (Relationship has ended), Syndax (Relationship has ended), Jazz Pharmaceuticals (Relationship has ended), Bristol Myers Squibb (Relationship has ended), BeiGene (Relationship has ended), Bergen Bio (Relationship has ended) |
| Vanessa Senatore | Planning Committee Member | Nothing to disclose |
| Jonathan Sokolowski, PhD | Planning Committee Member | Nothing to disclose |
To receive credit, attendees are required to participate in the webinar and complete the posttest and evaluation at www.ACHLcme.org. A certificate code will be provided at the end of the discussion with additional instructions. Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Texas MD Anderson Cancer Center designates this live activity will award 1.0 Nursing Contact Hours.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Magrolimab, sabatolimab, venetoclax are not FDA-approved for the treatment of HR-MDS
